Biossil Inc
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Biossil Inc - overview
Established
2023
Location
Toronto, ON, Canada
Primary Industry
Biotechnology
About
Based in Ontario, Canada, and founded in 2023 by co-founder and CEO Anthony Mouchantaf, JD, Biossil Inc. , a. k. a.
Biossil operates as a biotechnology company that focuses on developing therapies for biologically defined patient sub-populations in challenging diseases by leveraging its applied AI drug discovery platform. In October 2025, Galera Therapeutics, Inc. , a portfolio company of Bain Capital and Pacific Equity Partners, acquired Biossil Inc from Staircase Ventures. Financial terms of the transaction were not disclosed.
The company's Excavate software leverages a trillion-point multiomics pipeline alongside population-scale Electronic Medical Records (EMR) data to uncover disease variability and identify treatment-informing endotypes. Biossil's pipeline encompasses precision candidates targeting clinically variable diseases, with a focus on rare and neglected diseases, prophylactic vaccines, and chronic conditions exhibiting multiple disease phenotypes.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Bioinformatics
Website
www.biossil.co/
Verticals
Artificial Intelligence
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.